US approves joint damage data for Cosentyx
US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).
Read More
Tag: interleukin-17A
Lilly’s Taltz wins EU approval for psoriatic arthritis
Eli Lilly has been given a green light to market Taltz in the European Union as a treatment for psoriatic arthritis.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
